5 Comments

I worked for Roivant for about two years. They have been working since around 2020 on developing their own pipeline (rather than in-licensing), so the pre-clinical work is not off their radar, it is just hard. See the efforts of Proteovant and VantAI (targeted protein degradation), Psivant (computational drug discovery, descended from Silicon Therapeutics, which Roivant acquired in 2021), and Covant (covalent inhibitors).

Expand full comment

thanks! makes sense! I mostly focused on stuff that's already yielded some success. I am aware they are also trying to do more pre-clinical stuff, but that is a bit separate from their main thesis of "rescuing drugs". I might add this to the main piece.

Do you have any other comments? don't wanna be biased either way.

Expand full comment

In-depth piece. Appreciate it👍

Expand full comment

Thank you!

Expand full comment

> As for the let-down of the patients and their families that others have invoked: the entity on whom responsibility ultimately lies is the FDA, who agreed with the trial design. And last but not least, given the overall profiles of Axovant’s investors,

End of sentence lost?

Expand full comment